ERYTHROMYCIN ETHYLSUCCINATE

Search structure


Trade Names:	E.E.S. E.E.S. 200 E.E.S. 400 E-MYCIN E ERYPED ERYTHROMYCIN ETHYLSUCCINATE PEDIAMYCIN PEDIAMYCIN 400 WYAMYCIN E
Synonyms:	Arpimycin E.e.s. E.e.s. 200 E.e.s. 400 E-mycin E-mycin e Erymin Eryped Erythroden Erythromycin ethyl succinate Erythromycin ethylsuccinate Erythroped Erythroped a Erythroped fte Erythroped fte sf Erythroped pi Erythroped pi sf Erythroped sf NSC-756758 Pediamycin Pediamycin 400 Primacine Rommix 125 Sterile erythromycin ethylsuccinate Wyamycin Wyamycin e
Status:	Approved (1965)
Entry Type:	Small molecule
Molecule Category:	Salt
UNII:	1014KSJ86F
Parent Compound:	ERYTHROMYCIN

Structure


InChI Key	NSYZCCDSJNWWJL-YXOIYICCSA-N
Smile	CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C
InChI	InChI=1S/C43H75NO16/c1-15-29-43(11,52)36(48)24(5)33(47)22(3)20-41(9,51)38(25(6)34(26(7)39(50)57-29)59-32-21-42(10,53-14)37(49)27(8)56-32)60-40-35(28(44(12)13)19-23(4)55-40)58-31(46)18-17-30(45)54-16-2/h22-29,32,34-38,40,48-49,51-52H,15-21H2,1-14H3/t22-,23-,24+,25+,26-,27+,28+,29-,32+,34+,35-,36-,37+,38-,40+,41-,42-,43-/m1/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C43H75NO16
Molecular Weight	862.06
AlogP	2.68
Hydrogen Bond Acceptor	17.0
Hydrogen Bond Donor	4.0
Number of Rotational Bond	12.0
Polar Surface Area	226.28
Molecular species	NEUTRAL
Aromatic Rings	0.0
Heavy Atoms	60.0

Pharmacology

Action	Mechanism of Action	Reference
INHIBITOR	Bacterial 70S ribosome inhibitor	PubMed DailyMed

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides	-	2089	-	1610	31

Indications

Mesh Heading	Maximum Phase	Mesh ID	Reference
Diabetes Mellitus, Type 1	1	D003922	ClinicalTrials
Osteomyelitis	0	D010019	ClinicalTrials

Related Entries

Scaffolds

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Parent

Mixture

Adverse Reactions

SOC By Demographic Distribution

System Organ Classification (SOC)

	Relative Frequency (%)
General disorders and administration site conditions	19.18
Injury, poisoning and procedural complications	18.96
Gastrointestinal disorders	16.79
Respiratory, thoracic and mediastinal disorders	4.88
Psychiatric disorders	4.66
Immune system disorders	4.55
Skin and subcutaneous tissue disorders	4.44
Cardiac disorders	3.9
Nervous system disorders	3.36
Investigations	2.6
Metabolism and nutrition disorders	2.6
Musculoskeletal and connective tissue disorders	2.28
Product issues	2.28

Cross References

Resources	Reference
ChEBI	31555
ChEMBL	CHEMBL1200688
DrugCentral	1051
EPA CompTox	DTXSID4022993
FDA SRS	1014KSJ86F
KEGG	C12796
PubChem	443953
SureChEMBL	SCHEMBL18259
ZINC	ZINC000169356230

CONTENTS